Trial results for the MyLungHealth study, an intervention aimed at improving lung cancer screening rates, were posted on 2026-03-27, showing that the intervention arm identified 635 patients as newly eligible for lung cancer screening compared to 308 in the control arm.
Background
Early lung cancer screening (LCS) through low-dose computed tomography (LDCT) is a critical tool for detecting lung cancer at an earlier, more treatable stage. Despite its proven benefits, LCS remains underused due to various barriers. These challenges often include incomplete or inaccurate patient smoking data within electronic health records, which can hinder proper risk assessment, and limited time for clinicians to engage in shared decision-making with patients regarding screening. Addressing these barriers is essential to improve screening rates and ultimately reduce lung cancer mortality.
Trial design
This completed study, identified as Phase NA, enrolled a total of 31,303 participants with Lung Cancer or Lung Neoplasms/Diagnosis. The trial investigated MyLungHealth, a patient-centered intervention delivered through the patient portal. The intervention was designed to improve LCS rates by increasing the identification of eligible patients and facilitating informed decision-making. The study included two primary outcomes: for Study 1, the count of patients newly identified as eligible for lung cancer screening; and for Study 2, the count of participants for whom LDCT was ordered. Both studies compared an intervention arm against a control arm.
Key results
The trial results indicate the intervention's impact across several key measurements:
- For the Study 1 primary outcome, "Count of Patients Newly Identified as Eligible for Lung Cancer Screening," the Control Arm had 308 Participants, while the Intervention Arm had 635 Participants.
- For the Study 2 primary outcome, "Count of Participants for Whom LDCT Was Ordered," the Control Arm had 434 Participants, while the Intervention Arm had 474 Participants.
- For the Study 1 secondary outcome, "Count of Participants for Whom LDCT Eligibility Status Became Known," the Control Arm had 925 Participants, while the Intervention Arm had 3,570 Participants.
- For the Study 1 secondary outcome, "Count of Participants for Whom LDCT Was Ordered," the Control Arm had 350 Participants, while the Intervention Arm had 430 Participants.
- For the Study 1 secondary outcome, "Count of Participants for Whom LDCT Was Completed," the Control Arm had 226 Participants, while the Intervention Arm had 275 Participants.
- For the Study 2 secondary outcome, "Count of Participants for Whom LDCT Was Completed," the Control Arm had 290 Participants, while the Intervention Arm had 293 Participants.
What this means
The MyLungHealth intervention, delivered via a patient portal, appears to be effective in significantly improving the identification of patients eligible for lung cancer screening. The substantial increase in newly identified eligible patients (635 in the intervention arm versus 308 in the control arm) and the number of participants for whom LDCT eligibility status became known (3,570 versus 925) suggests that the intervention successfully addresses barriers related to patient data and informed decision-making. While the increase in LDCT orders and completions was more modest in Study 2, the overall trend indicates a positive impact on lung cancer screening rates. These findings suggest that patient-centered digital interventions can play a crucial role in enhancing early detection efforts for lung cancer.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06338592, titled "The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale," were posted on 2026-03-27 on clinicaltrials.gov.